Page 13 of 13: studies 121 to 130 of 130, newest first. Back to the ketamine for PTSD overview
Expert Review of Clinical Pharmacology December 17, 2017 Alexander M. Sherwood, Thomas E Prisinzano
Disrupted mental health affects up to one in three individuals globally and is an unmet medical challenge contributing to individual suffering as well as significant societal and economic burden [1...
Current Psychiatry Reports August 26, 2017 J. Krystal, Chadi G. Abdallah, Lynnette A. Averill et al.
Purpose of ReviewStudies of the neurobiology and treatment of PTSD have highlighted many aspects of the pathophysiology of this disorder that might be relevant to treatment. The purpose of this review is to highlight the potential clinical importance of an often-neglected consequence of stress models in animals that may be relevant to PTSD: the stress-related loss of synaptic...
July 1, 2017 B. Pradhan, Irving W. Wainer, Ruin Moaddel et al.
Background and objectives: Trauma memories lay at the core in etiopathogenesis of post-traumatic stress disorder (PTSD). Using pharmacological and cognitive behavioral treatments that specifically target trauma memories can improve the outcome. Ketamine has been shown to rapidly improve symptoms in PTSD and comorbid depression, but unfortunately these effects are short-lived. Trauma...
JAMA Psychiatry April 16, 2014 Adriana Feder, Michael K. Parides, James W. Murrough et al. 618 citations
IMPORTANCE: Few pharmacotherapies have demonstrated sufficient efficacy in the treatment of posttraumatic stress disorder (PTSD), a chronic and disabling condition. OBJECTIVE: To test the efficacy and safety of a single intravenous subanesthetic dose of ketamine for the treatment of PTSD and associated depressive symptoms in patients with chronic PTSD. DESIGN, SETTING, AND PARTICIPANTS:...
Pharmacopsychiatry September 1, 2005 Michael Schönenberg, Ursula Reichwald 1 citation
The NMDA receptor antagonist ketamine produces transient dissociative and psychotic states in healthy humans that resemble symptoms of posttraumatic stress disorder (PTSD). Thus, symptoms induced by severe stress or ketamine might both be related to altered glutamatergic neurotransmission. Since ketamine is used as an analgesic and sedative in emergency care, it might be one factor exacerbating...
October 1, 1999 R. Andrew Chambers, J. Douglas Bremner, Bita Moghaddam et al. 140 citations
Dissociative cognitive and perceptual alterations commonly occur at the time of traumatization and as an enduring feature of post-traumatic stress disorder (PTSD). After stress exposure, dissociative symptoms are a predictor of the development of PTSD. Recent preclinical data suggest that stress stimulates the cortico-limbic release of glutamate. The glutamate that is released during stress in...
Aaron Emile Philipp-Muller, Taras Reshetukha, Gustavo Vazquez et al.
BACKGROUND Over one third of patients with posttraumatic stress disorder (PTSD) do not respond to current interventions. Ketamine presents a potential treatment option; however, its effects are temporary. Administering ketamine alongside psychotherapy is one potential means of prolonging its effects; however, only a few studies have investigated this treatment method to date, and none have...
Michael Alvear preprint
Ketamine has emerged as a plausible rapid-acting treatment for post-traumatic stress disorder (PTSD), but the clinical literature is unusually easy to overstate because a small number of randomized trials are repeatedly represented across reviews, several publications reuse the same cohorts, and treatment studies are sometimes mixed with PTSD-prevention studies conducted around acute trauma....
Noam Goldway, Taly Markovits, Naomi Fine et al. preprint
Dissociation, an altered state of consciousness in which individuals feel detached from their body, environment, and sense of self, is a common feature of Post-Traumatic Stress Disorder (PTSD). Despite its significance, the neurocognitive processes underlying dissociation remain poorly understood, potentially limiting the effectiveness of PTSD diagnostics and treatment. To address this gap, we...
Acacia C Parks, Amanda L Woodward, Robert D Henry et al.
BACKGROUND Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and Post-Traumatic Stress Disorder (PTSD) are leading global causes of disability. Standard interventions often suffer from slow mechanisms of action, high attrition, and significant accessibility barriers. While intravenous (IV) and intranasal ketamine have emerged as rapid-acting alternatives, their high cost and...